Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29
Tip Ranks·- CMBI analyst Jill Wu reaffirmed a Buy rating on Sichuan Kelun-Biotech Biopharmaceutical and raised its target price from 507.11 HKD to 642.29 HKD. - The rating is driven by strong operational and clinical momentum, featuring better-than-expected sac-TMT commercialization and profit turnaround fueled by NRDL adoption. - Increased confidence in global and domestic Phase III clinical trials and Merck-led combination projects supports the higher valuation and blockbuster potential.HSI Up 291 pts; HSTI Up 72 pts; XIAOMI Up over 3%; WUXI BIO, WUXI APPTEC, BEIGENE, OOIL, TINGYI Hit New Highs
AASTOCKS News·- At the midday close, the Hang Seng Index rose 291 points to reach 25,786, while the Hang Seng Tech Index increased by 72 points to 4,754. - Major heavyweights such as XIAOMI, BABA, and TENCENT recorded solid gains alongside broader market movements. - Stocks including WUXI BIO, WUXI APPTEC, BEIGENE, OOIL, and TINGYI hit new highs during the trading session.